Introduction
Ion mobility spectrometry (IMS) [1] is a gas-phase electrophoretic technique which provides rapid separations of gas-phase ions on the milliseconds timescale. The theory and applications of IMS have been presented in a number of reviews [2-5]. Gas-phase ions introduced into the IMS spectrometer are accelerated through a drift tube, under the influence of a weak electric field gradient and in the presence of a neutral buffer gas (typically nitrogen, helium, or air), resulting in the separation of ions on the basis of differing mobilities. Ion mobility (K; cm 2 V -1 s -1 ), can be determined from the time taken for an ion to traverse the drift tube; (1)
where E (V cm -1 ) is the electric field experienced by the ion, v (V) is the total applied voltage used to create the electric field gradient in the drift cell, V d (cm s -1 ) is the average drift velocity of the ion, t d (s) is the ion drift time, and l (cm) is the length of the drift tube. The mobility of a gas phase ion is related to its collision cross section (i.e. size and shape) [6] ;
where z is the numerical charge, e is the charge on the ion, N is the number density of the buffer gas, μ is the reduced mass of the ion and buffer gas, k B the Boltzmann constant, T is the temperature, and Ω D is the collision cross-section.
IMS has been reported for the analysis of active pharmaceutical ingredients [7-10], veterinary drugs [11] , pesticides [12] and narcotics [13] [14] [15] [16] , using atmospheric or low pressure (< 10 Torr (1333 Pa)) drift tubes. Hyphenated instruments combining low field ion mobility separations with MS analysers (IM-MS) [17] have been used to identify pharmaceuticals [18] [19] [20] and narcotics [21] [22] [23] . Desorption electrospray-IM-MS has been reported for the direct analysis of active pharmaceutical ingredients in pharmaceutical formulations containing PEG [18] , demonstrating the benefits offered by ion mobility separations for pharmaceutical formulation analyses.
Currently IMS separations offer low full width at half height (FWHH) resolutions with typical values ranging from 10 -40, limiting the applications of this technique for the analysis of ions with the same charge and similar collision cross sections.
Increasing the electric field strength results in relatively higher resolving power (≈ 200) [24] . However, a consequence of high electric field strength is that the drift gas pressure must be increased proportionally to maintain a low E/N ratio (< 2 x 10 -17 V cm -2 ), required for field-independent mobilities, which may result in lower ion transmission. The temperature of the drift tube system may also be decreased to improve resolution, although this favours cluster formation making the identification of unknown samples difficult [25] . The use of drift gasses other than nitrogen, helium and air has also been used to enhance IMS separations [26, 27] . Hill and Asbury demonstrated that the selectivity of an IMS separation may be altered by employing drift gasses of different polarizability [28] .
An alternative approach to enhancing selectivity without altering the instrumental configurations is to use a shift reagent. A shift reagent is defined as a species that reacts or complexes with an analyte to form a gas-phase ion of lower mobility, which increases (shifts) drift time and enhances separation. [43, 44] and differential mobility spectrometry (DMS) [45] have also been used to characterise mixtures of PEG oligomers.
In this paper, we describe an IM-MS study of the gas-phase, non-covalent complexes of Lamivudine, an active pharmaceutical ingredient, with PEG oligomers and discuss the potential of PEGs as shift reagents to simplify and improve the selectivity for IM-MS analyses of formulated pharmaceutical ingredients.
Experimental

Materials
HPLC grade methanol and analytical reagent (AR) grade glacial acetic acid were purchased from Fisher Scientific (Loughborough, UK). Mass spectroscopy grade (Puriss, p.a.) formic acid and polyethylene glycol (average molecular weight 400)
were purchased from Sigma-Aldrich (Gillingham, UK). Distilled and deionised water was obtained in-house using a Triple Red water purification system (Triple Red, Long Crendon, UK). Lamivudine and Combivir tablets were obtained from GlaxoSmithKline (Stevenage, UK).
Sample preparation
Solutions of 49.5/49.5/1 (v/v/v) methanol/water/formic acid were used in all experiments. Stock solutions of Lamivudine (1 mg mL -1 ) were prepared in methanol and solutions of polyethylene glycol (2 mg mL -1 ) were prepared in distilled and deionised water. A stock solution of Combivir was prepared by grinding a Combivir tablet and dissolving in 100 mL of 49.5/49.5/1 (v/v/v) methanol/water/formic acid.
Aliquots of the Combivir stock solution were centrifuged (Eppendorf, Hamburg, Germany) at 13200 rpm for 3.5 mins to ensure that insoluble matter was not transferred to the mass spectrometer. The analysis of Combivr tablets was carried out using a Synapt IM-MS spectrometer [46] (Waters, Manchester, UK) operated in positive ion mode with the ESI capillary set to 3.0 kV. The nitrogen desolvation gas was set to 800 L hr -1 , the source temperature to 100 °C, the desolvation temperature to 150 °C, the cone voltage to 40 V and the nitrogen cone gas flow to 50 L hr -1 . The quadrupole mass filter was operated in wide-band-pass mode (analysing m/z 100 -1000). The nitrogen IMS gas flow was set to 20 mL min -1 and the IMS travelling wave velocity to 300 m s -1 with a wave height of 9.0 V. Single ion mobility spectra were acquired by measuring 200 sequential TOF pushes (45 μs). IM-MS data were accumulated for a 2 second scan time and processed automatically by combining the mass spectra for all ion mobility separations. Sample solutions were delivered from a gastight glass syringe (250 μL, SGE, Sydney, Australia) to the ESI probe by an integrated syringe pump (2 μL min -1 ).
For tandem mass spectrometric experiments the precursor ions were selected using the quadrupole mass filter, prior to acceleration into the trapping region (5 mL min -1 argon corresponding to a trap pressure of 2.98 x 10 -2 mbar (3.97 Pa), set to 25 V)
where they were subjected to partial fragmentation prior to entering the drift cell. Ions were mobility separated in the drift cell prior to undergoing further partial fragmentation in the transfer region (5 mL min -1 argon corresponding to a trap pressure of 2.98 x 10 -2 mbar (3.973 Pa), set to 6 V) and detected in the TOF region, providing drift time measurements and tandem mass spectra for the precursor ion and fragments created in the trapping region. Figure 2 and is located in a mobility and m/z area free from interfering PEG ions.
Results and discussion
Analysis of a pharmaceutical formulation containing Lamivudine
The experiments on complexation of Lamivudine with PEG were repeated for a Combivir tablet extract, which contained Lamivudine in the presence of PEG excipients, using a Waters Synapt spectrometer. Figure 5a shows the mass spectrum, 
